Zaiqi Wang has served as our chairman and CEO since November 2018.Prior to this, Dr. Zaiqi Wang served as GM, Roche China Innovation Center from 2017 to Nov 2018 where he managed 140 scientists and over 10 programs from discovery to early development. From 2011 to 2017, Dr. Zaiqi Wang served as Vice President at MSD China Development Center during which time he was responsible for all China clinical programs; key driver for NDA approval of Keytruda, Gardasil, Zepatir, Rotateq, Noxafil, Emend, Orgalutran and Bridion in China and led the overall Keytruda China development strategy, especially by driving melanoma as the leading indication. From 2001 to 2010, Dr. Zaiqi Wang was served as Director of Early Clinical Research and Experimental Medicine at Schering Plough where he was responsible for 7 FIH programs, and built up the translational research unit in Singapore, Chaired VLA-4 early development program and served as chair for protocol review committee for 2 years. Previously he was served as Assistant Clinical Pharmacologist, Phase 1 Unit at Eli Lilly from June 2001 to Dec 2001. Dr. Zaiqi Wang is Internist with board-certified Clinical Pharmacology in US and he received PhD in Biochemistry from Virginia Tech and pursued his Postdoc in John Hopkins University.

Francis Cao has served as our COO since 2018. Mr. Cao has over 15-year experience of operations, business development and management in biotech and pharmaceutical industry. From 2015 to 2018, Mr. Cao was Co-founder and CEO of Corestone Biosciences, Beijing. Prior to co-founding Corestone Bio, Mr. Cao held the Senior Director and also a Member of Corporate Management Committee position of BeiGene (NASDAQ: BGNE), a leading biopharmaceutical company in China. Prior to joining BeiGene, he held various managerial positions of business development, external scientific affairs, and investment in CapitalBio, GSK, and Johnson & Johnson. He received B.S. degree from Peking University in Biology and dual major in Economics. He enrolled in the PhD program at Department of Biology of Hong Kong University of Science and Technology and went to University of Pennsylvania School of Medicine as Visiting Scholar in 2003 and 2004.

James Mc Leod is a physician scientist and pharmaceutical executive with over 25 years of experience spanning preclinical and the phases of clinical development. Prior to joining InxMed, he was Chief Medical Officer and Senior VP at Galleon Pharmaceuticals and a consultant to small biotechnology companies and medical research foundations. He has headed the Experimental Medicine group at Merck Research Laboratories and the Early Clinical Research and Experimental Medicine group at the Schering-Plough Research Institute (SPRI).  He joined SPRI from Novartis in 2004, where he headed the Clinical Pharmacology, Experimental Clinical Pharmacology and Translational Medicine groups. He has extensive clinical development experience with individual or group leadership of 24 new drug approvals globally spanning all major therapeutic areas including gastroenterology and oncology medications.  James has degrees in Biomedical and Chemical Engineering (Rensselaer Polytechnic Institute) and Medicine (University of Connecticut) was medically boarded in internal medicine and endocrinology and metabolism. He has been a fellow in the Endocrinology & Metabolism and Human Genetics and has held faculty positions at the University of Pennsylvania and Northwestern University medical schools. He has been a member of ICH working groups and has co-chaired PhRMA and IQ Consortium innovation initiatives. He is a past chair of the PhRMA Clinical Pharmacology Technical Group.

Mr. Anfeng Guo will serve as our Chief Commercial Officer starting from September 2022. With over 20 years of experience in the pharmaceutical industry, Mr. Guo has developed a deep and sharp insight into this field. He was the VP and head of the Oncology Division and Liver Disease Division of BMS, and Senior Director of the Oncology Division of AZ, leading and participating in the listing of products including Opdivo, Tagrisso, Iressa, Baraclude, etc. For the recent two years, Mr. Guo, CCO of Linkdoc, has been leading the team building a digital Ecosystem for the pharmaceutical companys, clinical HCPs and researchers, and patients in the oncology field. Mr. Guo graduated from Nanjing Tech University, majoring in Pharmaceutical Microbiology. He also got a MBA from Nanjing University.

Leo Liu, Ph.D. has served as Chief Scientific Officer （CSO）, with 26 years of research experience in Pharmacology, Immunology and Oncology. Dr. Liu has deep understanding of immune-oncology, inflammatory autoimmune diseases, and strong experience in drug development, including 12 years of Pharmaceutical Industry R&D experience in leading and managing drug discovery and development programs for both small molecules and biologics, and 5 years of CRO service experience in Immuno-Oncology. He has served as Deputy Director of Research and Development of GSK, Director and Vice President of the Department of Tumor Immunology at Crown Bio and HDB. He has been focusing on the preclinical research and development of new tumor immunotherapeutic, and he is an expert in the field of tumor immunotherapy drug development. He graduated with a PhD in tumor immunology from Beijing Medical University. He did his postdoctoral fellowships in immunology at the Southwestern Medical Center of the University of Texas and the University of California at San Diego, and worked as an immunology researcher at NIH.

Dr. Jie Ding joined InxMed in January 2023. He spent more than twenty years in the pharmaceutical industry with experiences across the entire new medicine development spectrum from preclinical discovery research to late phase clinical development with multiple successful global NDA and sNDA registrations mainly in the oncology area. Dr. Ding started his career at GlaxoSmithKline (2002~2016). During 2007~2011, Dr. Ding was the lead Principle Statistician for the VEGF inhibitor Pazopanib in the Advanced RCC indication (approved by FDA in 2009) and several other indications including HCC, Thyroid, Sarcoma, etc. In 2016, Dr. Ding joined Merck & Co. (MSD), and his work directly led to FDA accelerated approval of Keytruda in the MSI-High Pan tumor indication (2017), the first ever pan tumor agnostic indication in history. From 2017 to 2021, Dr. Ding returned to Beijing and was Sr. Director and head of Biostatistics & Research Decision Science – Asia Pacific (BARDS-AP) at Merck (MSD). He and his team of 50+ statisticians and programmers in BARDS-AP successfully supported multiple NDA and sNDA including Keytruda and other medicines in the US, EU and Asia Pacific regions (China and Japan) in a little over three years. From 2021 to 2022, Dr. Ding was the Executive Director and head of Biostatistics at the Sumitomo Pharma Oncology in Cambridge, Massachusetts. Dr. Ding holds a Bachelor’s degree in Mathematics from Nankai University and a Ph.D. degree in Statistics from Temple University.